close
close

Shares of Boston Scientific Co. (NYSE:BSX) purchased by SVB Wealth LLC


SVB Wealth LLC has sold its interest in Boston Scientific Co. (NYSE:BSX – Free Report) increased 12.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,051 shares of the medical equipment supplier, having acquired an additional 1,503 shares during the period. SVB Wealth LLC’s holdings in Boston Scientific were worth $812,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in BSX. International Assets Investment Management LLC bought a new stake in shares of Boston Scientific in the first quarter worth about $54,000. Acadian Asset Management LLC bought a new stake in shares of Boston Scientific in the first quarter worth about $35,000. Prudential PLC bought a new stake in shares of Boston Scientific in the first quarter worth approximately $1,076,000. Cetera Investment Advisers increased its stake in Boston Scientific shares by 24.0% in the first quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment supplier valued at $1,275,000 after purchasing an additional 5,581 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Boston Scientific during the first quarter worth approximately $230,000. 89.07% of the shares are owned by hedge funds and other institutional investors.

Insider activity

In other news, EVP Wendy Carruthers sold 6,983 shares in a transaction that occurred on Friday, February 23rd. The shares sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission and accessible through the SEC’s website. In related news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock sold at an average price of $66.89, for a total transaction of $467,092.87. Following the sale, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The explanation of this sale can be found here. Insiders have sold 50,979 shares of the company worth $3,418,529 in the last ninety days. Currently, 0.50% of the shares are owned by insiders.

Wall Street analysts weigh in

A number of brokers have recently commented on BSX. JPMorgan Chase & Co. raised their target price on shares of Boston Scientific from $60.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, February 1. Mizuho upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $65.00 to $80.00 in a report on Thursday, February 1st. Citigroup raised their target price on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a report on Wednesday, April 3. BTIG Research re-rated a Buy rating and set a $64.00 price target on shares of Boston Scientific in a report on Friday, December 29. Finally, Wells Fargo & Company lifted their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $68.50.

Get our latest stock analysis on Boston Scientific

Boston Scientific trading down 0.1%

Shares of Boston Scientific opened at $67.33 on Friday. The company has a 50-day moving average of $67.25 and a 200-day moving average of $59.84. The stock has a market cap of $98.78 billion, a price-to-earnings ratio of 62.93, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX – Get Free Report) last reported its quarterly results on Wednesday, January 31. The medical device supplier reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.04. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period last year, the company earned earnings per share of $0.45. On average, research analysts expect Boston Scientific Co. will record a profit per share of 2.25 for the current financial year.

Boston Scientific Profile

(Free report)

Boston Scientific Corporation develops, manufactures and markets medical devices for use in various interventional medical specialties worldwide. It works through two segments, MedSurg and Cardiovascular. The company offers devices for diagnosing and treating gastrointestinal and pulmonary diseases, such as resolution clips, biliary stent systems, stents and electrocautery-enhanced delivery systems, direct visualization systems, digital catheters and single-use duodenoscopes; devices for the treatment of urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as a spinal cord stimulator system, proprietary programming software, a radio frequency generator, indirect decompression systems, exercise optimization tools and a deep brain stimulation system.

read more

Want to see which other hedge funds own BSX? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for Boston Scientific Co. (NYSE:BSX – Free Report).

Quarterly Institutional Ownership for Boston Scientific (NYSE:BSX)



Get news and reviews for Boston Scientific Daily – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Boston Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.